Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16154728 | 0.82 | PIK3CD (0.30) | — | |
| SCHEMBL16154712 | 0.82 | MAPK8 (0.33) | — | |
| SCHEMBL17616523 | 0.81 | — | — | |
| SCHEMBL16154718 | 0.78 | KCNA5 (0.36) | — | |
| SCHEMBL19788834 | 0.78 | — | — | |
| SCHEMBL16006511 | 0.78 | HTT (0.35) | HTTLMNA | |
| SCHEMBL19788773 | 0.78 | CRHR1 (0.34) | — | |
| SCHEMBL16154726 | 0.77 | LMNA (0.37) | HTTLMNA | |
| SCHEMBL15995887 | 0.77 | HTT (0.35) | HTTLMNA | |
| SCHEMBL16158063 | 0.75 | HTT (0.34) | HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312567-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11680064-B2 | Capsid inhibitors for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230038823-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20210009555-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2021-01-14 | — | — | US | disclosed |
| US-9951043-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9873680-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312567-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | HAVCR2, MAVS, CD4 | HTT 2128/4885LMNA 2645/4885 |
| US-20210009555-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | HTT 3665/4885LMNA 3197/4885 |
| US-20230038823-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | HAVCR2, MAVS, CD4 | HTT 2128/4885LMNA 2645/4885 |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | HTT 3558/4885LMNA 3225/4885 |
| US-11680064-B2 | Capsid inhibitors for the treatment of HIV | HAVCR2, MAVS, CD4 | HTT 2128/4885LMNA 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.